Puquitinib Mesylate

甲磺酸普喹替尼

Report date: 2022/10/25 13:05:20

NME

Base Information

Drug NamePuquitinib Mesylate

Drug Alias Name普喹替尼PuquitinibXC-302

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPI3-kinase class I inhibitorsPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 inhibitors +[4]

TargetsPI3-kinase class IPlatelet-derived growth factor receptorVascular endothelial growth factor receptor 2 +[4]

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesZhejiang Medicine Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A

Inactive CompaniesZhejiang Medicine Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A